

Vasily Shuvaev

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8873632/vasily-shuvaev-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19
papers

134
citations

5
h-index

11
g-index

22
ext. papers

165
ext. citations

2.1
avg, IF

1.51
L-index

#	Paper	IF	Citations
19	The use of non-cryopreserved hematopoietic stem cells for autologous transplantation in multiple myeloma patients. <i>Oncogematologiya</i> , 2022 , 17, 82-94	0.3	
18	National clinical recommendations for the diagnosis and treatment of mastocytosis. <i>Gematologiya i Transfuziologiya</i> , 2021 , 66, 280-311	0.4	0
17	Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. <i>Annals of Internal Medicine</i> , 2018 , 168, 461-470	8	78
16	Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy. <i>Blood</i> , 2018 , 132, 790-790	2.2	10
15	Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7003-7003	2.2	3
14	Russian Experience of Bosutinib Use in Chronic Myeloid Leukemia Patients in Routine Clinical Practice. <i>Blood</i> , 2018 , 132, 5446-5446	2.2	
13	Atypical Chronic Myeloid Leukemia Challenge in Russian Hematology Practice. <i>Blood</i> , 2018 , 132, 5483-5483		1
12	The Prognostic Significance of Minimal Residual Disease and Possibility of Its Correction in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 5751-5751	2.2	
11	Influence of Minimal Residual Disease on Survival of Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2018 , 132, 1611-1611	2.2	
10	ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, S222	2	2
9	The combination treatment regimen of ruxolitinib with low-dose mercaptopurine or cytarabine in frail patients with blast-phase myelofibrosis. <i>British Journal of Haematology</i> , 2017 , 178, 645-646	4.5	3
8	Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase. <i>Blood</i> , 2016 , 128, 1891-1891	2.2	8
7	Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop. <i>Blood</i> , 2016 , 128, 792-792	2.2	15
6	Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7054-7054	2.2	4
5	Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission. <i>Blood</i> , 2015 , 126, 3293-3293	2.2	2
4	Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 4051-4051	2.2	6
3	Frequent Mutations and Their Influence on Prognosis in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 4949-4949	2.2	

- 2 The Influence of Hemostasis Genetic Features on Thrombosis Rates in Patients with Polycythemia Vera. *Blood*, **2015**, 126, 5180-5180 2.2
- 1 Genetic and Epigenetic Alterations of Ph-Negative Myeloproliferative Neoplasms. *Blood*, **2014**, 124, 5549-5549